Abstract
A large‐scale open‐label trial conducted at electroconvulsive therapy (ECT) clinics has found that twice‐weekly dosing of ketamine was noninferior to three sessions a week of ECT in patients with treatment‐resistant major depression. Relapse rates during a 6‐month follow‐up period after the initial 3‐week treatment period were higher among patients receiving ECT than patients receiving ketamine. Study results were published May 24, 2023, in the New England Journal of Medicine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
